Hope or hype : the obsession with medical advances and the high cost of false promises / / Richard A. Deyo, Donald L. Patrick.

Saved in:
Bibliographic Details
:
TeilnehmendeR:
Year of Publication:2005
Language:English
Online Access:
Physical Description:xvi, 335 p. :; ill.
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05131nam a22004574a 4500
001 5003001805
003 MiAaPQ
005 20200520144314.0
006 m o d |
007 cr cn|||||||||
008 040922s2005 nyua sb 001 0 eng
010 |z  2004022295 
020 |z 0814408451 
035 |a (MiAaPQ)5003001805 
035 |a (Au-PeEL)EBL3001805 
035 |a (CaPaEBR)ebr10075614 
035 |a (CaONFJC)MIL112625 
035 |a (OCoLC)748521033 
040 |a MiAaPQ  |c MiAaPQ  |d MiAaPQ 
050 4 |a RA418.5.M4  |b D49 2005 
082 0 4 |a 610/.28  |2 22 
100 1 |a Deyo, Richard A. 
245 1 0 |a Hope or hype  |h [electronic resource] :  |b the obsession with medical advances and the high cost of false promises /  |c Richard A. Deyo, Donald L. Patrick. 
260 |a New York :  |b AMACOM, American Management Association,  |c c2005. 
300 |a xvi, 335 p. :  |b ill. 
504 |a Includes bibliographical references (p. [291]-326) and index. 
505 0 |a Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 
505 0 |a Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from "experimental" to "standard care" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 
533 |a Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. 
650 0 |a Medical innovations  |z United States  |x Evaluation. 
650 0 |a Medical technology  |z United States  |x Evaluation. 
650 0 |a Medical care  |x Technological innovations  |z United States  |x Evaluation. 
650 0 |a Medical care  |z United States  |x Evaluation. 
650 0 |a Medical innovations  |x Economic aspects  |z United States. 
650 0 |a Medical technology  |z United States  |x Cost effectiveness. 
650 0 |a Medical care  |x Technological innovations  |z United States  |x Cost effectiveness. 
650 0 |a Medical care, Cost of  |z United States. 
655 4 |a Electronic books. 
700 1 |a Patrick, Donald L. 
710 2 |a ProQuest (Firm) 
856 4 0 |u https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3001805  |z Click to View